Recent advances in tumor hypoxia: Tumor progression, molecular mechanisms, and therapeutic implications

Medical Science Monitor

Volumn 13, Issue 10, 2007, Pages

  Zhang, Yuqing ^a   Li, Min ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; HIF 1; Hypoxia; Tumor; VEGF

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOMYCIN; CARBONATE DEHYDRATASE IX; CYTOKINE; DX 21; FUMAGILLOL CHLOROACETYLCARBAMATE; GELDANAMYCIN; GLUCOSE TRANSPORTER 1; GLYCOLYTIC ENZYME; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; KF 58333; MISONIDAZOLE; MONOCLONAL ANTIBODY DC101; OXYGEN; PACLITAXEL; PX 478; RADICICOL; SEMAXANIB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; VINCRISTINE; WORTMANNIN;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; ELECTRON SPIN RESONANCE; GASTROINTESTINAL TUMOR; HUMAN; HYPOXEMIA; MACROPHAGE; MOLECULAR BIOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; OXYGEN TISSUE LEVEL; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR GROWTH;

ANIMALS; ANOXIA; DISEASE PROGRESSION; HUMANS; NEOPLASMS; OXYGEN; TUMOR CELLS, CULTURED;

EID: 35549000083     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med, 1997; 3: 177-82
2. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res, 1989; 49: 6449-65
3. Bacon AL, Harris AL: Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med, 2004; 36: 530-39
4. Holmquist L, Lofstedt T, Pahlman S: Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. Adv Exp Med Biol, 2006; 587: 179-93
5. Suzuki Y, Nakano T, Ohno T et al: Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. Int J Gynecol Cancer, 2006; 16: 306-11
6. Harrison LB, Chadha M, Hill RJ et al: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist, 2002; 7: 492-508
7. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res, 1994; 6: 509-18
8. Rupec RA: The genomic response of tumour cells to hypoxia and reoxygenation: differential activation of transcription factors AP-1 and NF-kB. Med Sci Monit, 1996; 2: 6-13
9. Al-Waili NS, Butler GJ, Beale J et al: Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit, 2005; 11(9): RA279-89
10. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst, 2001; 93: 266-76
11. Menon C, Fraker DL: Tumor oxygenation status as a prognostic marker. Cancer Lett, 2005; 221: 225-35
12. Vaupel P, Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist, 2004; 9(Suppl.5): 4-9
13. Gallez B, Baudelet C, Jordan BF: Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed, 2004; 17: 240-62
14. Krause BJ, Beck R, Souvatzoglou M, Piert M: PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging, 2006; 50: 28-43
15. Sloka JS, Hollett PD, Mathews M: A Quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit, 2007; 13(3): RA37-46
16. Christian N, Bol A, De Bast M et al: Determination of tumour hypoxia with the PET tracer [(18)F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging, 2007 Mar 3; [Epub ahead of print]
17. Matsumoto K, Szajek L, Krishna MC et al: The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol, 2007; 30: 873-81
18. Papadopoulou MV, Pouremad R, Bloomer WD, Wyrwicz A: Novel noninvasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model. Anticancer Res, 2006; 26: 3259-63
19. Olive PL, Aquino-Parsons C: Measurement of tumor hypoxia using single-cell methods. Semin Radiat Oncol, 2004; 14: 241-48
20. Chapman JD, Engelhardt EL, Stobbe CC et al: Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol, 1998; 46: 229-37
21. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P: Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res, 2005; 65: 7259-66
22. Hodgkiss RJ: Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des, 1998; 13: 687-702
23. Juhasz M, Chen J, Lendeckel U et al: Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther, 2003; 18: 837-46
24. Bache M, Reddemann R, Said HM et al: Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys, 2006; 66: 1481-87
25. Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood, 2004; 104: 2224-34
26. Seo SB, Jeong HJ, Chung HS et al: Inhibitory effect of high molecular weight water-soluble chitosan on hypoxia-induced inflammatory cytokine production. Biol Pharm Bull, 2003; 26: 717-21
27. Garayoa M, Martinez A, Lee S et al: Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol, 2000; 14: 848-62
28. Kunz M, Ibrahim SM: Molecular responses to hypoxia in tumor cells. Mol Cancer, 2003; 2: 23-35
29. Minet E, Mottet D, Michel G et al: Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett, 1999; 460: 251-56
30. Semenza GL: Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda), 2004; 19: 176-82
31. Lee H, Paik SG: Regulation of BNIP3 in normal and cancer cells. Mol Cells, 2006; 21: 1-6
32. Zundel W, Schindler C, Haas-Kogan D et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev, 2000; 14: 391-96
33. Douglas RM, Haddad GG: Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. J Appl Physiol, 2003; 94: 2068-83
34. Waite KA, Eng C: Protean PTEN: form and function. Am J Hum Genet, 2002; 70: 829-44
35. Schmid T, Zhou J, Brune B: HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med, 2004; 8: 423-31
36. Powis G, Kirkpatrick L: Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther, 2004; 3: 647-54
37. Hanahan D, Christofori G, Naik P, Arbeit J: Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer, 1996; 32A: 2386-93
38. Bunn HF, Poyton RO: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev, 1996; 76: 839-85
39. Strauss L, Volland D, Kunkel M, Reichert TE: Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit, 2005; 11(8): BR280-92
40. Nakashima T, Huang CL, Liu D et al: Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit, 2004; 10(6): BR157-65
41. An WG, Kanekal M, Simon MC et al: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature, 1998; 392: 405-8
42. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 1999; 13: 9-22
43. Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med, 2003; 54: 17-28
44. Cao Y, Linden P, Shima D et al: In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest, 1996; 98: 2507-11
45. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol, 1995; 268: C1362-68
46. Duffy JP, Eibl G, Reber HA, Hines OJ: Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer, 2003; 2: 12-21
47. Garcea G, Doucas H, Steward WP et al: Hypoxia and angiogenesis in pancreatic cancer. ANZ J Surg, 2006; 76: 830-42
48. Lewis C, Murdoch C: Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol, 2005; 167: 627-35